I was looking at nutraceutical companies on the NYSE and they seemed to have PE ratios of about 35. That accords very closely with your assumptions in terms of end MCAP of $70m.
I do wonder whether your revenue assumptions may prove to be on the low side though
- Forums
- ASX - By Stock
- NZS
- 4c fair value ($30M), 8c short term target ($60M)
4c fair value ($30M), 8c short term target ($60M), page-23
-
- There are more pages in this discussion • 2,062 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NZS (ASX) to my watchlist
|
|||||
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.334M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
NZS (ASX) Chart |
Day chart unavailable
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online